T1	Outcomes 73 102	on early virological response
T2	Outcomes 267 309	increases early virological response (EVR)
T3	Outcomes 730 736	[SA]).
T4	Outcomes 737 740	HCV
T5	Outcomes 786 793	and 12.
T6	Outcomes 794 832	Ribavirin plasma trough concentrations
T7	Outcomes 981 1056	received nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens
T8	Outcomes 1072 1100	achieved an HCV RNA decrease
T9	Outcomes 1166 1183	P=0.017), but EVR
T10	Outcomes 1301 1327	of faster HCV RNA decrease
T11	Outcomes 1365 1377	younger age.
T12	Outcomes 1378 1386	RBV-C(4)
T13	Outcomes 1568 1589	a greater decrease in
T14	Outcomes 1641 1656	into higher EVR
T15	Outcomes 1735 1762	might improve HCV treatment
